A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models
| dc.contributor.author | Lei, Wei | |
| dc.contributor.author | Vekariya, Rakesh H. | |
| dc.contributor.author | Ananthan, Subramaniam | |
| dc.contributor.author | Streicher, John M. | |
| dc.date.accessioned | 2020-09-10T21:54:43Z | |
| dc.date.available | 2020-09-10T21:54:43Z | |
| dc.date.issued | 2020-01 | |
| dc.identifier.citation | Lei, W., Vekariya, R. H., Ananthan, S., & Streicher, J. M. (2020). A novel mu-delta opioid agonist demonstrates enhanced efficacy with reduced tolerance and dependence in mouse neuropathic pain models. The Journal of Pain, 21(1-2), 146-160. | en_US |
| dc.identifier.issn | 1526-5900 | |
| dc.identifier.pmid | 31201990 | |
| dc.identifier.doi | 10.1016/j.jpain.2019.05.017 | |
| dc.identifier.uri | http://hdl.handle.net/10150/643323 | |
| dc.description.abstract | Numerous studies have demonstrated a physiological interaction between the mu opioid receptor (MOR) and delta opioid receptor (DOR) systems. A few studies have shown that dual MOR-DOR agonists could be beneficial, with reduced tolerance and addiction liability, but are nearly untested in chronic pain models, particularly neuropathic pain. In this study, we tested the MOR-DOR agonist SRI-22141 in mice in the clinically relevant models of HIV Neuropathy and Chemotherapy-Induced Peripheral Neuropathy (CIPN). SRI-22141 was more potent than morphine in the tail flick pain test and had equal or enhanced efficacy versus morphine in both neuropathic pain models, with significantly reduced tolerance. SRI-22141 also produced no jumping behavior during naloxone-precipitated withdrawal in CIPN or nayve mice, suggesting that SRI-22141 produces little to no dependence. SRI-22141 also reduced tumor necrosis factor-alpha and cyclooxygenase-2 in CIPN in the spinal cord, suggesting an anti-inflammatory mechanism of action. The DOR-selective antagonist naltrindole strongly reduced CIPN efficacy and anti-inflammatory activity in the spinal cord, without affecting tail flick antinociception, suggesting the importance of DOR activity in these models. Overall, these results provide compelling evidence that MOR-DOR agonists could have strong efficacy with reduced side effects and an anti-inflammatory mechanism in the treatment of neuropathic pain. Perspective: This study demonstrates that a MOR-DOR dual agonist given chronically in chronic neuropathic pain models has enhanced efficacy with strongly reduced tolerance and dependence, with a further anti-inflammatory effect in the spinal cord. This suggests that MOR-DOR dual agonists could be effective treatments for neuropathic pain with reduced side effects. (C) 2020 U.S. Association for the Study of Pain. Published by Elsevier Inc. All rights reserved. | en_US |
| dc.description.sponsorship | National Institutes of Health | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier BV | en_US |
| dc.rights | Copyright © 2020 U.S. Association for the Study of Pain. Published by Elsevier Inc. All rights reserved. | en_US |
| dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | en_US |
| dc.subject | Mu opioid receptor | en_US |
| dc.subject | delta opioid receptor | en_US |
| dc.subject | HIV neuropathy | en_US |
| dc.subject | chemotherapy-induced neuropathy | en_US |
| dc.subject | tolerance | en_US |
| dc.subject | dependence | en_US |
| dc.subject | neuroinflammation | en_US |
| dc.title | A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models | en_US |
| dc.type | Article | en_US |
| dc.contributor.department | Univ Arizona, Coll Med, Dept Pharmacol | en_US |
| dc.identifier.journal | JOURNAL OF PAIN | en_US |
| dc.description.note | 12 month embargo; published 12 June 2019 | en_US |
| dc.description.collectioninformation | This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu. | en_US |
| dc.eprint.version | Final accepted manuscript | en_US |
| dc.identifier.pii | S152659001930745X | |
| dc.source.journaltitle | The Journal of Pain | |
| dc.source.volume | 21 | |
| dc.source.issue | 1-2 | |
| dc.source.beginpage | 146 | |
| dc.source.endpage | 160 | |
| refterms.dateFOA | 2020-06-12T00:00:00Z |
